Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor
HOUSTON, TX--(Marketwired - January 10, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are …